Complications of serogroup B meningococcal disease in survivors: A review

Infectious Disorders - Drug Targets

Volumn 14, Issue 3, 2014, Pages 205-212

  Dastouri, Fereshteh ^a,b   Hosseini, Ahmad Mirmohammad ^c   Haworth, Elizabeth ^d   Khandaker, Gulam ^a,b,e   Rashid, Harunor ^a,b,e   Booy, Robert ^a,b,e  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e University of Sydney   (Australia)

Author keywords

Complications; Meningococcal disease; Serogroup B

Indexed keywords

AGE; AMPUTATION; ARTICLE; COGNITIVE DEFECT; DATA EXTRACTION; DATA SYNTHESIS; DISEASE ASSESSMENT; GENDER; HEARING IMPAIRMENT; HUMAN; INFECTIOUS COMPLICATION; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; PHYSICAL DISABILITY; SEIZURE; SEROGROUP B MENINGOCOCCAL DISEASE; SEROTYPE; SYSTEMATIC REVIEW; VACCINATION; VISUAL IMPAIRMENT; ADOLESCENT; ADULT; AGED; CHILD; COMPLICATION; EPIDEMIC MENINGITIS; INFANT; MIDDLE AGED; NEWBORN; PRESCHOOL CHILD; PREVALENCE; STATISTICS AND NUMERICAL DATA; SURVIVOR; YOUNG ADULT;

MENINGOCOCCUS VACCINE;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; INFANT, NEWBORN; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; MIDDLE AGED; NEISSERIA MENINGITIDIS, SEROGROUP B; PREVALENCE; SURVIVORS; VACCINATION; YOUNG ADULT;

EID: 84928887125     PISSN: 18715265     EISSN: 18755852     Source Type: Journal    
DOI: 10.2174/1871526515999150320155614     Document Type: Article

References (41)

1. Meningococcal disease/Meningococcal Vaccines for Australians: Information for Immunisation Providers: National Centre for Immunisation Research and Surveillance(NCIRS), fact sheet, November, 2009.
2. Edmond, K.; Clark, A.; Korczak, V. S.; Sanderson, C.; Griffiths, U. K.; Rudan, I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. Lancet infect. Dis., 2010, 10(5), 317-28.
3. Moxon, R.; Snape, M. D. The price of prevention: what now for immunisation against meningococcus B? Lancet, 2013, 382 (9890), 369-70.
4. Viner, R. M.; Booy, R.; Johnson, H.; Edmunds, W. J.; Hudson, L.; Bedford, H.; Kaczmarski, E.; Rajput, K.; Ramsay, M.; Christie, D. Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study. Lancet Neurol., 2012, 11(9), 774-83.
5. Roed, C.; Omland, L. H.; Skinhoj, P.; Rothman, K. J.; Sorensen, H. T.; Obel, N. Educational achievement and economic self sufficiency in adults after childhood bacterial meningitis. J.A.M.A., 2013, 309(16), 1714-21.
6. Vermunt, L. C.; Buysse, C. M.; Joosten, K. F.; Oranje, A. P.; Hazelzet, J. A.; Verhulst, F. C.; Utens, E. M. Self-Esteem in Children and Adolescents After Septic Shock Caused by Neisseria meningitidis: Scars Do Matter. J. Adolesc. Health., 2008, 42(4), 386-93.
7. Lahra, M. M.; Enriquez, R. P. Annual report of the Australian meningococcal surveillance programme, 2011. Commun. Dis. Intell. Quarterly Report, 2012, 36(3), E251.
8. Halperin, S. A.; Bettinger, J. A.; Greenwood, B.; Harrison, L. H.; Jelfs, J.; Ladhani, S. N.; McIntyre, P.; Ramsay, M. E.; Sáfadi, M. A. The changing and dynamic epidemiology of meningococcal disease. Vaccine, 2012, 30, B26-B36.
9. Khatami, A.; Pollard, A. J. The epidemiology of meningococcal disease and the impact of vaccines. Expert. Rev. Vaccines., 2010, 9(3), 285-98.
10. Meningococcal meningitis. http://www.who.int/mediacentre/factsheets/fs141/en/index.html. (Accessed April 12, 2014).
11. Garralda, M. E.; Gledhill, J.; Nadel, S.; Neasham, D.; O'Connor, M.; Shears, D. Longer-term psychiatric adjustment of children and parents after meningococcal disease. Pediatr. Crit. Care. Med., 2009, 10(6), 675-80.
12. Bacterial Meningitis. http://www.who.int/nuvi/meningitis/en/index.html (Accessed June 18, 2014).
13. Nadel, S. Prospects for eradication of meningococcal disease. Arch. Dis. Child., 2012, 97(11), 993-8.
14. du Plessis, M.; Moodley, C.; Mothibeli, K. M.; Fali, A.; Klugman, K. P.; Von Gottberg, A. Population Snapshot of Invasive Serogroup B Meningococci in South Africa from 2005 to 2008. Eur. J. Clin. Microbiol., 2012, 50(8), 2577-84.
15. Granoff, D. M. Review of meningococcal group B vaccines. Clinical Infect. Dis., 2010; 50 (Supplement 2), S54-S65.
16. JPT, C. H. H.; Green, S. Cochrane handbook for systematic reviews of interventions version 5.1. 0 updated March 2011]. The Cochrane Collaboration Syst. Rev., 2011.
17. Ottawa Hospital Research Institute. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in metaanalyses. (Accessed 10 September 2014).
18. Wallace, B. C.; Schmid, C. H.; Lau, J.; Trikalinos, T. A. Meta- Analyst: software for meta-analysis of binary, continuous and diagnostic data. B.M.C. Med. Res. Methodol., 2009, 9(1), 80.
19. Borg, J.; Christie, D.; Coen, P. G.; Booy, R.; Viner, R. M. Outcomes of meningococcal disease in adolescence: prospective, matched-cohort study. Pediatrics, 2009, 123(3), e502-e509.
20. Dawson, J.; Wardle, R. Detection and prevalence of hearing loss in a cohort of children following serogroup B, meningococcal infection 1983–1987. Public Health., 1990, 104(2), 99-102.
21. Moss, P. Outcome of meningococcal group B meningitis. Arch. Dis. Child., 1982, 57(8), 616-21.
22. Howitz, M.; Lambertsen, L.; Simonsen, J.; Christensen, J.; Mølbak, K. Morbidity, mortality and spatial distribution of meningococcal disease, 1974–2007. Epidemiol. Infect., 2009, 137(11), 1631-40.
23. Buysse, C. M.; Oranje, A. P.; Zuidema, E.; Hazelzet, J. A.; Hop, W. C.; Diepstraten, A. F.; Joosten, K. F. Long-term skin scarring and orthopaedic sequelae in survivors of meningococcal septic shock. Arch. Dis. Child., 2009, 94(5), 381-6.
24. Gottfredsson, M.; Reynisson, I. K.; Ingvarsson, R. F.; Kristjansdottir, H.; Nardini, M. V.; Sigurdsson, J. F.; Schneerson, R.; Robbins, J. B.; Miller, M. A. Comparative long-term adverse effects elicited by invasive group B and C meningococcal infections. Clin. Infect. Dis., 2011, 53(9), e117-e124.
25. Cabellos, C.; Nolla, J.; Verdaguer, R.; Pelegrin, I.; Ribera, A.; Ariza, J.; Viladrich, P. Arthritis related to systemic meningococcal disease: 34 years’ experience. Eur. J. Clin. Microbiol., 2012, 31(10), 2661-6.
26. Edwards, M. S.; Baker, C. J. Complications and sequelae of meningococcal infections in children. J. Pediatr., 1981, 99(4), 540-5.
27. Erickson, L.; De Wals, P. Complications and sequelae of meningococcal disease in Quebec, Canada, 1990–1994. Clinical Infect. Dis., 1998, 26(5), 1159-64.
28. Drake, R.; Dravitski, J.; Voss, L. Hearing in children after meningococcal meningitis. J. Paediatr. Child Health., 2000, 36(3), 240-3.
29. Wang, B.; Haji Ali Afzali, H.; Marshall, H. The inpatient costs and hospital service use associated with invasive meningococcal disease in South Australian children. Vaccine, 2014, 32(2014), 4791-8.
30. Ramakrishnan, M.; Ulland, A. J.; Steinhardt, L. C.; Moïsi, J. C.; Were, F.; Levine, O. S. Sequelae due to bacterial meningitis among African children: a systematic literature review. B.M.C. Med., 2009, 7(1), 47.
31. Baraff, L. J.; Lee, S. I.; Schriger, D. L. Outcomes of bacterial meningitis in children: a meta-analysis. Pediatr. Infect. Dis. J., 1993, 12(5), 389-94.
32. Balmer, P.; Borrow, R.; Miller, E. Impact of meningococcal C conjugate vaccine in the UK. J. med. microbiol., 2002, 51(9), 717-22.
33. Invasive meningococcal infections laboratory reports in England and Wales, by capsular group & epidemiological year, 1998/99-2012/13. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/343375/Table_1a_Invasive_meningococcal__E_W_by _capsular_group___epi_year.pdf (Accessed October 31, 2014).
34. Gilca, R.; Deceuninck, G.; Lefebvre, B.; Tsang, R.; Amini, R.; Gilca, V.; Douville-Fradet, M.; Markowski, F.; De Wals, P. The changing epidemiology of meningococcal disease in Quebec, Canada, 1991–2011: potential implications of emergence of new strains. PloS one, 2012, 7(11), e50659.
35. Andrews, S. M.; Pollard, A. J. A vaccine against serogroup B Neisseria meningitidis: dealing with uncertainty. Lancet infect. dis., 2014, 14(5), 426-34.
36. Dang, V.; Jamieson, F. B.; Wilson, S.; Rawte, P.; Crowcroft, N. S.; Johnson, K.; Tsang, R. S.; Deeks, S. L. Epidemiology of serogroup B invasive meningococcal disease in Ontario, Canada, 2000 to 2010. B.M.C. Infect. Dis., 2012, 12(1), 202.
37. Snape, M. D.; Pollard, A. J. The beginning of the end for serogroup B meningococcus? Lancet, 2013, 381(9869), 785-7.
38. Serruto, D.; Bottomley, M. J.; Ram, S.; Giuliani, M. M.; Rappuoli, R. The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens. Vaccine, 2012, 30, B87-B97.
39. Robinson, J. L. Immunization for meningococcal serogroup B: What does the practitioner need to know? Paediatr. Child Health., 2014, 19(2), 91-8
40. JCVI position statement on the use of meningococcal B (MenB) vaccine in the UK. https://www.gov.uk/government/publications/ meningococcal-b-vaccine-jcvi-position-statement (Accessed May 12, 2014).
41. Liberati, A.; Altman, D. G.; Tetzlaff, J.; Mulrow, C.; Gøtzsche, P. C.; Ioannidis, J. P.; Clarke, M.; Devereaux, P.; Kleijnen, J.; Moher, D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann. Intern. Med., 2009, 151(4), W-65- W-94.